Related Experiment Video
Updated: Jul 4, 2026
03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Gene therapy for esophageal squamous cell carcinoma
Hideaki Shimada1, Takenori Ochiai
1Department of Frontier Surgery, Chiba University Graduate School of Medicine. 1-8-1 Inohana Chuo-ku Chiba-shi, Chiba, Japan. hshimada@faculty.chibau.jp
Summary
Gene therapy using Ad5CMV-p53 significantly suppressed esophageal cancer cell growth. This p53 gene therapy shows promise for treating advanced esophageal cancer, with a clinical trial underway.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Advanced esophageal cancer, particularly T4 tumors, has a poor prognosis despite current treatments.
- Esophageal cancer exhibits specific genetic alterations, including p53 mutations and aberrant angiogenesis.
- Gene therapy offers a novel strategy targeting the molecular underpinnings of esophageal cancer.
Purpose of the Study:
- To review molecular events in esophageal cancer.
- To evaluate the efficacy of p53 gene therapy using Ad5CMV-p53 in esophageal cancer.
- To assess the tolerability and efficacy of p53 gene therapy in a clinical trial for unresectable advanced esophageal cancer.
Main Methods:
- Analysis of p53 genetic alterations and angiogenesis in esophageal cancer.
- In vitro evaluation of Ad5CMV-p53 (p53 recombinant adenoviral vector) on human esophageal squamous cell carcinoma cell lines.
- Phase I/II clinical trial enrolling 10 patients with unresectable advanced esophageal cancer to assess vector tolerability and efficacy.
Main Results:
- Ad5CMV-p53 infection led to significant growth suppression in human esophageal squamous cell carcinoma cell lines.
- The p53 gene therapy agent Ad5CMV-p53 demonstrates potential for locally advanced esophageal cancer.
- A Phase I/II clinical trial was initiated to evaluate p53 gene therapy in patients with unresectable advanced esophageal cancer.
Conclusions:
- Ad5CMV-p53 is a potential therapeutic agent for locally advanced esophageal cancer.
- Further research into combination gene therapies and adjuvant gene therapy with radiation is warranted.
- Clinical trials are essential for evaluating the safety and efficacy of p53 gene therapy in esophageal cancer patients.
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:21Barrett Esophagus-II: Clinical Manifestations and Management
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Esophageal Achalasia
Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide (VIP)...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...